Unicycive Therapeutics, Inc.

4300 El Camino Real, Suite 210

Los Altos, CA 94022

November 18, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance
100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

Re:

Unicycive Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-283210
Filed November 13, 2024

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Unicycive Therapeutics, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Wednesday, November 20, 2024, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the registration statement has been declared effective pursuant to this acceleration request.

	Very truly yours,

	UNICYCIVE THERAPEUTICS, INC.


	By:	/s/ Shalabh Gupta
	Name:	Shalabh Gupta
	Title:	Chief Executive Officer

cc: Jeffrey Fessler, Sheppard Mullin Richter & Hampton LLP